Loading...
XJPX
4571
Market cap67mUSD
Dec 05, Last price  
148.00JPY
1D
-0.67%
1Q
-3.27%
Jan 2017
-83.35%
IPO
-37.90%
Name

NanoCarrier Co Ltd

Chart & Performance

D1W1MN
XJPX:4571 chart
P/E
—
P/S
96.54
EPS
—
Div Yield, %
—
Shrs. gr., 5y
2.77%
Rev. gr., 5y
-27.80%
Revenues
109m
-19.92%
262,718,000353,648,000117,820,00084,337,000346,344,000373,778,000472,197,000675,801,000243,344,000218,694,000259,097,000496,732,000552,973,000313,264,000264,032,000202,189,000135,508,000108,516,000
Net income
-835m
L+7.10%
-494,032,000-524,480,000-494,790,000-555,178,000-398,003,000-484,446,000-1,113,687,000-207,156,000-2,537,148,000-2,676,049,000-5,416,808,000-1,808,510,000-2,009,676,000-2,835,793,000-1,881,678,000-1,310,976,000-780,002,000-835,380,000
CFO
-402m
L-31.36%
-588,172,000-456,620,000-451,997,000-579,113,000-293,705,000-635,329,000-1,086,613,000-1,120,686,000-1,971,089,000-2,525,557,000-4,927,585,000-2,037,259,000-1,138,665,000-1,247,432,000-1,752,992,000-1,087,051,000-585,081,000-401,617,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

NanoCarrier Co., Ltd. researches, develops, produces, and sells pharmaceuticals using micelle nanoparticle technology primarily for the treatment of cancer in Japan. The company's product pipeline includes VB-111 non-proliferative adenovirus vector, which is in phase III clinical trials for the treatment of ovarian cancer, as well as in phase II clinical trials for treatment of rGBM and colorectal cancer; ENT103 Otolaryngology product that is in phase III clinical trials for the treatment of otitis media; NC-6004 Cisplatin micelle, which is in phase II clinical trials for the treatment of head and neck cancer; NC-6300 Epirubicin micelle that is in phase I clinical trials for the treatment of hemangiosarcoma; and NC-6100 PRDM14 (siRNA), which is in phase I clinical trials for the treatment of breast cancer. Its product pipeline also comprises TUG1 (ASO) for glioblastoma and RUNX1 (mRNA) for osteoarthritis of the knee that are in preclinical stage. The company was founded in 1996 and is headquartered in Tokyo, Japan.
URL
https://www.nanocarrier.co.jp/
IPO date
Mar 05, 2008
Employees
17
Domiciled in
JP
Incorporated in
JP

Valuation

Title
JPY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑032024‑032023‑032022‑032021‑032020‑032019‑032018‑032017‑032016‑03
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT